Vault Bioventures was hired to build a 5-year, U.S. strategic and life cycle plan for a top 20 global pharmaceutical company’s newly launched prescription product, which entered a highly competitive and minimally differentiated product category – in a top five therapy class.
Our client had previously managed strategic and life cycle planning via their internal global team. Under-performing U.S. launch results warranted a new strategic approach focused upon product differentiation and patient focus. The Vault Bioventures team conducted an assessment of the clinical development program and created a new life cycle planning process for a regional affiliate.
Based on a significant gap in available and impactful clinical data, our team recommended several Phase IV and pre-clinical studies to support product differentiation. Subsequent market research evaluated the updated target product profile and demonstrated increased intent to use, among key customer segments. As a result of positive customer feedback and the impact on future business, our recommendations were activated in the new life cycle plan.
Due to the effectiveness of our 5-year U.S. strategic and life cycle plan, Vault Bioventures was retained to lead global strategy and life cycle planning for the same product. Vault Bioventures conducted a clinical and commercial evaluation of the global opportunity and identified significant opportunities for value creation via further enhancement of the product profile to demonstrate clinical differentiation and appropriate patient segments.